新型重组高效复合干扰素对宫颈癌细胞的生长抑制及促凋亡作用  

The Growth Inhibition and Apoptosis-promoting Effect of rSIFN-co to the Cervical Carcinoma Cells in Vitro

作　　者：陈妍[1] 欧阳运薇[1] 潘小玲[1] 刘霞[1] 赖曾珍[1] 

机构地区：[1]四川大学华西第二医院,四川成都610041

出　　处：《实用妇产科杂志》2009年第4期216-219,I0001,共5页Journal of Practical Obstetrics and Gynecology

基　　金：四川省科技攻关课题资助(04SG022-010)

摘　　要：目的:探讨新型重组高效复合干扰素对宫颈癌Caski细胞的作用,并与同类型复合干扰素、普通重组Ⅰ型干扰素、化疗药物对比。方法:应用新型重组高效复合干扰素、复合α干扰素、干扰素α-2b和顺铂以0.156μg/ml、0.625μg/ml、2.5μg/ml及10μg/ml浓度作用于体外培养的Caski细胞72小时后,MTT法检测并计算细胞抑制率并比较。应用新型重组高效复合干扰素、复合α干扰素、干扰素α-2b和顺铂以0.156μg/ml、0.625μg/ml、2.5μg/ml浓度作用于体外培养的Caski细胞72小时后,以流式细胞仪检测Caski细胞的凋亡率并进行比较。结果:几种干扰素及顺铂均能导致Caski细胞生长抑制及促进细胞凋亡,相同浓度条件下,新型重组高效复合干扰素和顺铂对Caski细胞的抑制及凋亡作用强于复合α干扰素和干扰素α-2b的作用,尤以顺铂的作用最强。结论:重组高效复合干扰素对体外培养的宫颈癌Caski细胞的生长有抑制作用,并能促进Caski细胞凋亡;作用虽然不及化疗药物顺铂,但较同类型干扰素、普通重组Ⅰ型干扰素的作用强。Objective： To investigate the effect of rSIFN-co, consensus Interferon （ Infergen）, IFNα-2b （ Interferon α-2b） and chemotherapeutics on cervical cancer cell line Caski in vitro. Methods： After Caski cervical cancer cells were cultured in vitro with rSIFN-co, Infergen, IFNα-2b and cisplatin （DDP） at the concentration of 0.156 μg/ml, 0.625 μg/ml,2.5 μg/ml and 10 μg/ml respectively for 72 hours,cell proliferation was mensurated by MTT assay,cell inhibition rathe was calculated. Then after Caski cervical cancer cells were treated with rSIFN-co, Infergen, IFNα-2b and DDP at the concentration of 0.156 μg/ml,0.625 μg/ml,2.5 μg/ml for 72 hours, cell apoptosis was determined by flow cytometry. Results： rSIFN-co, Infergen, IFNα-2b and DDP could induce inhibition and apoptosis of Caski cells. The inhibition and apoptosis of Caski cells which had been induced by rSIFN-co and DDP were better than which had been induced by Infergen and IFNα-2b at the same concentration, and DDP was more better than rSIFN- co. Conclusions： rSIFN-co has antineoplastic effect by inhibiting proliferation and inducing apoptosis in Caski cervical cancer cell in vitro. The effect is inferior to DDP, but better than the same type interferon and general type Ⅰ interferon.

关 键 词：干扰素 宫颈癌 基因重组 

分 类 号：R737.33[医药卫生—肿瘤]